(Q33427321)

English

A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joanne E Mortimer

object named as

Joanne Mortimer

5

0 references

author name string

Sam Joseph Lubner

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jacqueline Mullvain

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Scott Perlman

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael Pishvaian

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Katherine Oliver

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jennifer Heideman

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lance Hall

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jamey Weichert

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Glenn Liu

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

4 November 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer Investigation

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

483-489

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

131I-tositumomab therapy as initial treatment for follicular lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Alpha emitter radium-223 and survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Bone-targeting radiopharmaceuticals including radium-223.

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Edelfosine is incorporated into rafts and alters their organization

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Disruption of cellular cholesterol transport and homeostasis as a novel mechanism of action of membrane-targeted alkylphospholipid analogues

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Lipid rafts and clusters of apoptotic signaling molecule-enriched rafts in cancer therapy.

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy.

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Localized well-differentiated thyroid carcinoma: survival analysis of prognostic factors and (131)I therapy.

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Physical models and dose factors for use in internal dose assessment

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Perspectives of novel imaging techniques for staging, therapy response assessment, and monitoring of surveillance in lung cancer: summary of the Dresden 2013 Post WCLC-IASLC State-of-the-Art Imaging Workshop.

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Developments in the internal dosimetry of radiopharmaceuticals

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Phospholipid ether analogs for the detection of colorectal tumors

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Fluorescent Cancer-Selective Alkylphosphocholine Analogs for Intraoperative Glioma Detection

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Synthesis and structure-activity relationship effects on the tumor avidity of radioiodinated phospholipid ether analogues

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Cytotoxicity of an Anti-cancer Lysophospholipid through Selective Modification of Lipid Raft Composition

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Effect of anti-tumor ether lipids on ordered domains in model membranes

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2015.1081691

21 January 2018

Identifiers

10.3109/07357907.2015.1081691

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33427321&oldid=1605987339"